Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI

American Journal of Roentgenology

Volumn 197, Issue 1, 2011, Pages

  Suh, Young Joo ^a   Kim, Myeong Jin ^a   Choi, Jin Young ^a   Park, Young Nyun ^a,b   Park, Mi Suk ^a   Kim, Ki Whang ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Contrast material; Hepatocellular carcinoma; MRI; Sensitivity; Specificity

Indexed keywords

GADOXETIC ACID;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HEPATOBILIARY RADIOGRAPHY; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE QUALITY; LIVER CELL CARCINOMA; LIVER INJURY; LIVER NODULE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVER VARIATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOCAL NODULAR HYPERPLASIA; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; LIVER CIRRHOSIS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 79960536183     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.10.5845     Document Type: Article

References (29)

1. Seale MK. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. RadioGraphics 2009; 29:1725-1748
2. Cruite I, Schroeder M, Merkle EM, Sirlin CB. Gadoxetate disodium-enhanced MRI of the liver. Part 2. Protocol optimization and lesion appearance in the cirrhotic liver. AJR 2010; 195:29-41
3. Ringe KI, Husarik DB, Sirlin CB, Merkle EM. Gadoxetate disodium-enhanced MRI of the liver. Part 1. Protocol optimization and lesion appearance in the noncirrhotic liver. AJR 2010; 195:13-28
4. Motosugi U, Ichikawa T, Sou H, et al. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 2010; 256:151-158
5. Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010; 255:459-466
6. Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol 2008; 43:504-511
7. Halavaara J, Breuer J, Ayuso C, et al. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT-a multicenter trial. J Comput Assist Tomogr 2006; 30:345-354 (Pubitemid 43922248)
8. Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology 2005; 237:89-98 (Pubitemid 41346150)
9. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT - initial observations. Radiology 2005; 234:468-478 (Pubitemid 40139918)
10. Kim SH. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR 2009; 192:1675-1681
11. Fujita M, Yamamoto R, Fritz-Zieroth B. Contrast enhancement with Gd-EOB-DTPA in MR imaging of hepatocellular carcinoma in mice: a comparison with superparamagnetic iron oxide. J Magn Reson Imaging 1996; 6:472-477 (Pubitemid 126707482)
12. Shimofusa R, Ueda T, Kishimoto T, et al. Magnetic resonance imaging of hepatocellular carcinoma: a pictorial review of novel insights into pathophysiological features revealed by magnetic resonance imaging. J Hepatobiliary Pancreat Surg 2010; 17:583-589
13. Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009; 44:793-798
14. Tsuboyama T, Onishi H, Kim T, et al. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging - correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 2010; 255:824-833
15. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236 (Pubitemid 43112690)
16. Ni Y, Chen F, Wang H, Feng Y, Li J, Jiang Y. Proper definitions of MRI contrast enhancement in liver tumors. J Gastroenterol 2010; 45:349-350
17. Ishigami K, Yoshimitsu K, Nishihara Y, et al. Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. Radiology 2009; 250:435-443
18. van den Bos IC, Hussain SM, Dwarkasing RS, et al. MR imaging of hepatocellular carcinoma: relationship between lesion size and imaging findings, including signal intensity and dynamic enhancement patterns. J Magn Reson Imaging 2007; 26:1548-1555 (Pubitemid 350291283)
19. Kojiro M. "Nodule-in-nodule" appearance in hepatocellular carcinoma: its significance as a morphologic marker of dedifferentiation. Intervirology 2004; 47:179-183 (Pubitemid 39279457)
20. Goshima S, Kanematsu M, Matsuo M, et al. Nodule-in-nodule appearance of hepatocellular carcinomas: comparison of gadolinium-enhanced and ferumoxides-enhanced magnetic resonance imaging. J Magn Reson Imaging 2004; 20:250-255 (Pubitemid 38970933)
21. Schuhmann-Giampieri G, Schmitt-Willich H, Press W, Negishi C, Weinmann H, Speck U. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992; 183:59-64
22. van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide OATP1. J Pharmacol Exp Ther 1999; 290:153-157 (Pubitemid 29302315)
23. Leonhardt M, Keiser M, Oswald S, et al. Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporter. Drug Metab Dispos 2010; 38:1024-1028
24. Grazioli L, Morana G, Kirchin MA, Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005; 236:166-177 (Pubitemid 40853309)
25. Karam AR, Shankar S, Surapaneni P, Kim YH, Hussain S. Focal nodular hyperplasia: central scar enhancement pattern using gadoxetate disodium. J Magn Reson Imaging 2010; 32:341-344
26. Giovanoli O, Heim M, Terracciano L, Bongartz G, Ledermann H. MRI of hepatic adenomatosis: initial observations with gadoxetic acid contrast agent in three patients. AJR 2008; 190:1340; [web]W290-W293 (Pubitemid 351684910)
27. Siegelman ES. Body MR techniques and MR of the liver. In: Siegelman ES, ed. Body MRI. Philadelphia. PA: Elsevier Saunders, 2005:1-63
28. Hussain SM, van den Bos IC, Dwarkasing RS, Kuiper J-W, Hollander JD. Hepatocellular adenoma: findings at state-of-the-art magnetic resonance imaging, ultrasound, computed tomography and pathologic analysis. Eur Radiol 2006; 16:1873-1886 (Pubitemid 44193172)
29. Huppertz A, Balzer T. Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid enhanced MR images with intraoperative findings. Radiology 2004; 230:266-275 (Pubitemid 37549812)